Publications by authors named "Peta Edler"
Article Synopsis
- This study investigates the effectiveness and safety of different primaquine dosing strategies in preventing relapsing Plasmodium vivax malaria in children under 15 years.
- A systematic review was conducted, analyzing various studies involving children treated with primaquine, focusing on those who received treatment over multiple days and were followed up for at least 28 days.
- The findings from 3514 children across 27 studies were compiled to analyze different dosing regimens, assess the risk of recurrent malaria, and evaluate tolerability and safety concerning adverse effects.
Influenza exposures early in life are believed to shape future susceptibility to influenza infections by imprinting immunological biases that affect cross-reactivity to future influenza viruses. However, direct serological evidence linked to susceptibility is limited. Here we analysed haemagglutination-inhibition titres in 1,451 cross-sectional samples collected between 1992 and 2020, from individuals born between 1917 and 2008, against influenza B virus (IBV) isolates from 1940 to 2021.
View Article and Find Full Text PDFArticle Synopsis
- The cohealth Health Concierge program in Melbourne aimed to support culturally diverse residents in navigating health services during the COVID-19 pandemic from July 2020 to June 2022.
- Through a mixed-methods evaluation involving thousands of interactions and surveys, the program was found to effectively promote COVID-safe behaviors and improve access to health services, particularly vaccinations.
- While the initiative received initial positive feedback, some residents felt it lacked adaptability over time, highlighting the need for better-defined management and the importance of bicultural workers for continued support.
Article Synopsis
- The study investigates the safety of primaquine, a medication used to eliminate dormant liver-stage parasites of Plasmodium vivax, focusing on its impact on hemolysis risk.
- Researchers conducted a systematic review and meta-analysis of clinical studies published from 2000 to 2023, including data on patients treated with different primaquine regimens.
- The main outcome measured was the significant reduction in hemoglobin levels (more than 25% to below 7 g/dL) by day 14 post-treatment, with analysis based on the G6PD enzyme activity levels in patients.
Background: Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear. We undertook a systematic review and individual patient data meta-analysis to investigate the efficacy and tolerability of different primaquine dosing regimens to prevent P vivax recurrence.
Methods: For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023.